Serine protease (TPS): A diagnostic and prognostic marker in pediatric patients with acute non-lymphoblastic leukemia  by Agwa, Sara H.A. et al.
The Egyptian Journal of Medical Human Genetics (2011) 12, 165–170Ain Shams University
The Egyptian Journal of Medical Human Genetics
www.ejmhg.eg.net
www.sciencedirect.comORIGINAL ARTICLESerine protease (TPS): A diagnostic and prognostic
marker in pediatric patients with acute non-lymphoblastic
leukemiaSara H.A. Agwa a, Nihal S. El-Kinawy b,*, Ahmad A. Shuoyb ca Medical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt
b Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
c Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, EgyptReceived 16 April 2011; accepted 2 July 2011
Available online 23 September 2011*
K
E-
11
El
Pe
doKEYWORDS
Serine protease;
Tryptase (TPS);
RT-PCR;
ANLL;
Prognosis;
OutcomeCorresponding author. Add
ourba, Heliopolis, Egypt. Te
mail address: kinawynihal@
10-8630  2011 Ain Shams
sevier B.V. All rights reserve
er review under responsibilit
i:10.1016/j.ejmhg.2011.07.00
Production and hress: 6 A
l.: +002
yahoo.co
Universit
d.
y of Ain
4
osting by EAbstract The Serine protease, TPS (tryptase), is a speciﬁc marker for mast cells and mast cell-
associated disorders. However, substantial amounts of TPS are also expressed in neoplastic
myeloid, non-mast cell lineage. The aim of this study is determination and quantitation of TPS
expression in patients with acute non-lymphoblastic leukemia (ANLL); to evaluate its prognostic
value and its relevance as a genetic marker for detection of minimal residual blast cells. Reverse
transcriptase-polymerase chain reaction (RT-PCR) was used to detect levels of TPS from 30 newly
diagnosed ANLL children and 10 normal children served as controls. TPS levels for positive cases
were reevaluated after induction chemotherapy; after onset of relapse or by the end of the study.
Our results showed that the gene transcripts were detected in 56.7% of patients but were not
expressed by normal controls. The highest frequency of TPS was recorded in patients with M4
showing signiﬁcantly higher levels compared to other FAB (French–American–British Classiﬁca-
tion) subtypes. TPS levels were directly correlated to TLC, absolute blast counts in peripheral
blood, levels of CD34 and CD117. After induction chemotherapy, levels of TPS decreased signiﬁ-
cantly in those who achieved complete remission while it increased signiﬁcantly in relapsed patients,bdel-salam Zaki Street, El-
180578877.
m (N.S. El-Kinawy).
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166 S.H.A. Agwa et al.with a risk estimate of relapse six times higher in positive cases than TPS negative patients. 84.6% of
the patients negative for TPS achieved complete remission with better disease free survival. In con-
clusion, TPS is expressed in a group of patients with ANLL thus serves as a disease related marker;
it could be used as a prognostic indicator in evaluating remission status and early relapse as its ele-
vated levels are associated with high risk of relapse; again, it is useful in predicting disease outcome.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Acute non-lymphoblastic leukemia (ANLL) is characterized
by clonal proliferation of immature myeloid cells without sig-
niﬁcant differentiation [1]. Despite maturation arrest, blast
cells in ANLL are often capable of expressing lineage-re-
stricted differentiation antigens [2]. The prognosis and clinical
picture in ANLL varies, depending on deregulated genes, cell
type(s) involved and the speciﬁc biological properties of the
clone(s) [3].
Tryptase are lineage-associated serine proteases primarily
expressed in mast cells, and less abundantly in blood basophils
[4]. The genes of TPS (a and b) cluster on the short arm of hu-
man chromosome 16 [5] most of the a-TPS product is enzymat-
ically inactive (a-proTPS) and is released spontaneously by
mast cells [6], while most of the b-TPS product is enzymatically
active tetramers stored in cytoplasmic granules and released
during degranulation [7]. Under physiologic conditions other
myeloid cells are virtually TPS negative [8]. Later, it was found
that myeloblasts in a group of patients with ANLL produce
signiﬁcant amounts of TPS [9] which induce a number of
growth regulators involved in the survival and proliferation
of blast cells [10].
In the present study, we try to detect and to quantitate the
TPS expression in newly diagnosed Egyptian children with
ANLL, to investigate its usefulness as a tool for diagnosis
and prognosis of ANLL and as a marker of the disease
outcome.2. Subjects and methods
2.1. Subjects
This study was carried out on 30 newly diagnosed ANLL pa-
tients presenting to Hematology Oncology Clinic of Pediatrics
Department, Ain Shams University Hospitals during the peri-
od between May 2008 and March 2010. Their mean age was
7.1 ± 4.3 years with a male:female ratio of (1.3:1). Ten age
and sex matched normal subjects were included as controls.
Parents of all participants signed an informed consent before
starting the study. Exclusion criteria included patients with
drug-related ANLL, biphenotypic leukemia, those having
allergic reactions, helminthic infestations and renal disease.
The diagnosis of ANLL was based according to the standard
morphological and immunophenotypic criteria proposed by
the French–American–British (FAB) cooperative study group
(from M0 to M7).
According to the TPS gene expression, the patient group
was subdivided into either negative or positive cases. Positive
cases at presentation were re-evaluated for TPS mRNA after
induction chemotherapy; if relapse occur during the follow
up period or by the end of the study.All patients except those with M3 received the standard
induction protocol for ANLL, two cycles (3 + 7) consisting
of daunorubicin 45 mg/m2 for 3 days and cytosine arabinoside
100 mg/m2/12 h for 7 days, followed by three cycles of consol-
idation cycle (A) consists of vepsid and adriamycin, cycle (B)
consists of high dose cytosine arabinoside (1 gm/m2/12 h) for
5 days followed by cycle (A) again. Patients with M3 received
all-trans retinoic acid. Patients were followed up for a period
of 12–24 months.
2.2. Methods
2.2.1. Sampling
Three milliliter anticoagulated EDTA blood were collected
from all subjects, 2 ml for CBC and Leishman stained smears
and 1 ml for DNA extraction and detection of TPS mRNA.
One milliliter of bone marrow (BM) or peripheral blood was
used for immunophenotyping (IPT) from patients only.
2.2.2. Baseline assessment
All patients were subjected to: full history taking, thorough
clinical examination and laboratory investigations including
complete blood picture and blood smears using Coulter Coun-
ter Gen-S (Coulter Electronics Corporation, Hielach, Florida,
USA).
2.2.3. Bone marrow (BM)
Aspiration for detection of inﬁltration by P20% blast cells of
all nucleated BM cells and immunophenotypic analysis per-
formed by multicolor direct immunoﬂuorescence cytometry
using Coulter EPICS XL ﬂow cytometer (Florida, USA).
The panel of MoAbs used for each sample includes: CD34,
HLA-DR, CD13, CD33, CD14, CD15, CD7, and CD117.
2.2.4. Detection of TPS messenger RNA (mRNA)
Using reverse transcriptase-polymerase chain reaction (RT-
PCR) [11] for patients and controls. Isolation of peripheral
blood mononuclear cells (MNC) was performed by density
gradient centrifugation using Ficoll Hypaque 1077 (Sigma
USA) at 1200g for 30 min at 40 C, the interface cells were
removed, washed twice with 25 ml sterile PBS (pH:7.3), Isola-
tion of peripheral blood mononuclear cells (MNC) was per-
formed by density gradient centrifugation using Ficoll
Hypaque 1077 (Sigma, USA) at 1200g for 30 min at 40 C,
the interface cells were removed, washed twice with 25 ml ster-
ile PBS (pH:7.3), pelleted and re-suspended in 1 ml PBS. The
cells were re-centrifuged at 1200g for 2 min then kept at
800 C until RNA extraction.
Total nuclear RNA was extracted using RNA Extraction
kit (Qiagen). The isolated RNA was re-suspended in RNAse-
free water and stored at 80 C until assay. The RNA concen-
tration was assessed by absorbance reading at 260 nm with UV
spectrophotometry (Beckman; DU series 650, INC, USA).
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ried out in 20 ll reaction mixture by using ﬁrst strand cDNA
synthesis kit (Promega USA) according to manufacturer
instruction.
PCRampliﬁcationwas performed using the selectedTPS pri-
mer pairs (59 primer: 59-GAGGCCCCCAGGAGCAAGTG-
39; 39 primer: 59-ACATCGC-CCCAGCCAGTGAC-39), and
b-actin gene, a house keeping gene used as an internal control
(59 primer: 59-AGGCCGGC-TTCGCGGGCGAC-39; 39 pri-
mer: 59-CTCGGGAGCCACCAGCAGCTC-39).
A 5 ll of ﬁrst strand cDNA was used as a template for the
PCR reaction. Each reaction mixture consisted of 0.5 mM of
each primer, 10· Taq Buffer, 2.5 mM dNTP mix, 0.5 U of
Taq polymerase and nuclease free water to a ﬁnal volume of
50 ll.
Thermocycling, using PTC 200 (MJ Research, Inc., Boston,
Mass.), consisted of 32 PCR cycles (94 C for 1 min, 63 C for
1 min, and 72 C for 90 s; initial denaturation step at 95 C for
1 min). After ampliﬁcation, PCR products were subjected to
gel electrophoresis and visualized by ethidium bromide stain-
ing. Detection of a band at 383 bp indicated TPS gene ampli-
ﬁcation while b-actin gene was visualized at 200 bp (Fig 1).
They were semiquantitated by the UVP Gel-Document System
(GDS 8000). No template cDNA samples were used as nega-
tive control.
To normalize the difference in RNA degradation for indi-
vidual samples and in RNA loading for RT-PCR, the values
of TPS gene expression were divided by b-actin gene values
in each sample and were deﬁned as TPS gene expression levels.
2.3. Statistical analysis
Data were analyzed using the statistical soft ware SPSS (version
10), results were expressed as mean values ± standard error of
mean (SED). Student’s t test was used for comparison between
two sets of parametric data. Chi square (v2) test was performed
to compare between non-parametric data. Pearson’s correlation
(r) test was used for correlations between different parameters.
Event free survival and overall survival were measured from
start of disease until disease relapse/death or till the end of the
study over a period of 12–24 months. Survival analysis was esti-
mated using Kalpan–Meier curve. p-Value <0.05 was consid-
ered signiﬁcant.TPS PCR product  
β-actin PCR product 
400 pb 
   1      2         3        4        5         6 
200 pb 
Figure 1 Electrophoretic separation of PCR ampliﬁed products.
Lane 1: molecular DNA marker. Lanes 2, 4, and 5: cases showing
positive TPS gene transcript and b-actin. Lane 3: negative control
(blank). Lane 6: case showing b-actin only.3. Results
The results of this study are summarized in Tables 1–4 and
Figs. 1 and 2.
TPS together with b-actin genes expression were detected in
17 cases (56.7%) while all controls were negative for TPS
showing b-actin gene only (Fig. 1). The TPS transcripts were
particularly expressed with FAB groups M0 (4 of 5 patients),
M1 (3 of 7), M2 (4 of 8), M3 (1 of 2) and was found in all
M4 patients. But it was not expressed by M5 nor M6 subtypes.
On comparing the hematological parameters in both groups,
total leukocytic counts (TLC) were signiﬁcantly higher while
hemoglobin levels and platelet counts were signiﬁcantly lower
in patients expressing TPS (p< 0.05; Table 1). The TPS
mRNA levels were higher in M4 patients (12.1 ± 3.4 · 102)
compared to those detected in other FAB subtypes
(4.6 ± 1.3 · 102) with a statistical signiﬁcant difference
(t= 2.39; p= 0.03; Table 2). Correlative studies showed that
TPS levels were positively correlated with TLC; absolute blast
counts in peripheral blood (PB), CD34, and CD117 levels (Ta-
ble 3).
After the ﬁrst induction chemotherapy cycle, the gene
expression for the positive cases was reassessed and revealed
low values of TPS in 8 patients (0.71 ± 0.26 · 102) while
the other nine showed elevated levels (13.3 ± 3.04 · 102) with
a statistical signiﬁcant difference (t= 4.15; p= 0.004); 5 of
these 9 patients showed incomplete remission by BM examina-
tion, while the other four were morphologically in complete
remission (BM blasts <5%), yet. TPS mRNA remained highly
expressed. During the follow up period, all of the nine cases
relapsed.
84.6% of TPS negative patients showed complete remission
(CR) which is statistically better outcome than positive cases
(Table 4). Moreover, negative cases for TPS had longer overall
survival (9.8 ± 0.58 months) than positive cases (6.9 ± 0.
52 months) with a statistical signiﬁcant difference (t= 3.73;
p= 0.001). Survival analysis was estimated using Kalpan–Me-
ier curve (Fig. 2). The risk estimate for relapse in patients
expressing TPS was six times higher than those who were not
expressing TPS with a 95% conﬁdence interval CI (5.46–8.0).5. Discussion
Despite progress in understanding molecular biology of
ANLL, its treatment remains challenging. Advances in under-
standing the pathophysiology of ANLL may lead to improve-
ments in survival of these patients [12], thus identiﬁcation of
new molecular markers for sub-classiﬁcation and risk assess-
ment is critical. Recent data suggested that the serine protease,
tryptase, is expressed in a group of patients with ANLL and
that its level reﬂects the burden of leukemic cells [3].
In the present study, TPS transcripts were expressed by
56.7% of patients but they were not expressed totally in con-
trols. Also, in previous studies [5,10] the expression of TPS
was conﬁned to ANLL patients but not in controls nor in
ALL groups. This proves that TPS is produced by leukemic
myeloid blasts, which reﬂects inherent ability to produce
TPS, and its speciﬁcity to myeloid cells. On the other hands,
other investigators [8] showed that TPS was expressed in only
39% of cases. This discrepancy was due to the higher sensitiv-
ity of the PCR used in this report compared to other methods
Table 3 Correlation between TPS levels and other prognostic
factors in patients group.
Parameters TPS gene expression levels
r p S
Age (years) 0.17 0.37 NS
TLC (·109/L) 0.48 0.007* HS
Hemoglobin (g/dl) 0.286 1.25 NS
Platelets (·103ml) 0.231 0.22 NS
AbsolutePB blasts (·109/l) 0.427 0.01* S
BM blasts(%) 0.204 0.28 NS
CD34 (%) 0.485 0.007* HS
HLA-DR (%) 0.328 0.07 NS
CD117 (%) 0.414 0.02* S
TLC, total leukocytic counts; PB, peripheral blood; BM, bone
marrow; S, signiﬁcant; HS, highly signiﬁcant; NS, non-signiﬁcant.
* Signiﬁcance level: p< 0.05.
Table 1 Comparative study of TPS gene expression in patients group and other hematological parameters at presentation.
Parameters TPS gene expression
Negative (13) X± SED/n (%) Positive (17) X± SED/n (%) t-Test or v2 p
Age (years) 6.41 ± 0.95 7.84 ± 1.2 0.91 0.36
Gender male 17 10 (58.8) 7 (53.8)
female 13 7 (41.2) 6 (46.2) 10.74 0.538
TLC (·109/l) 7.8 ± 2.3 34.9 ± 11.1 2.38 0.02*
Hemoglobin (g/dl) 7.9 ± 0.5 5.6 ± 0.5 3.02 0.006*
Platelets (·103ml) 60.8 ± 11.3 30.5 ± 4.3 2.03 0.02*
Absolute PB blasts (·109/l) 4.6 ± 1.2 17.8 ± 10.5 0.96 1.23
BM blasts (%) 62.3 ± 5.1 66.6 ± 5.4 0.53 0.57
CD34 n
5 3 (17.6) 2 (15.4) 0.869 0.633
25+ 14 (82.4) 11 (84.6)
HLA-DR n
4 1 (5.9) 1 (7.7) 0.844 0.68
26+ 18 (94.1) 12 (92.3)
CD117 n
4 1 (5.9) 3 (23.1) 1.88 0.29
26+ 16 (94.1) 10 (76.9)
FAB n
5 M0 1 (7.7) 4 (23.5)
7 M1 4 (30.8) 3 (17.7)
8 M2 4 (30.8) 4 (23.5)
2 M3 1 (7.7) 1 (5.9)
5 M4 – 5 (29.4)
2 M5 2 (15.3) – 12.6 0.04*
1 M6 1 (7.7) –
TPS levels (·102) – 7.53 ± 1.79
TLC, total leukocytic counts; PB, peripheral blood; BM, bone marrow; FAB, French–American–British Classiﬁcation; M, myeloid.
* Signiﬁcance level: p< 0.05.
Table 4 TPS gene expression among the studied group and
patients’ outcome during the follow up period.
Fate of patients TPS gene expression
Negative cases (13) Positive cases (17)
No. % No. %
CR 11 84.6 8 47.1
Relapse/Death 2 15.4 9 52.9
X2test 4.47
p value 0.04*
CR, complete remission.
* Signiﬁcance level: p< 0.05.
Table 2 Comparative study of TPS mRNA transcripts levels
in different FAB subtypes in patients group.
TPS gene expression levels (·102) t-Test p
M4 12.1 ± 3.4
M0, 1, 2, 3 4.6 ± 1.3 2.39 0.03*
FAB, French–American–British Classiﬁcation; M, myeloid.
* Signiﬁcance level: p< 0.05.
168 S.H.A. Agwa et al.used (immunohistochemistry or Northern blot analysis). In the
current study, TPS expression showed a statistical signiﬁcant
association with FAB subtypes; it was expressed among all
M4 patients, 80% of M0; 42.9% of M1; 50% of M2 subtype
and in one patient with M3 similar results were reported pre-
viously [3], and added that TPS expression in M4 is indicative
of minimal differentiation along the mast cell pathway but the
maturation arrest did not allow for terminal differentiation
and maturation [5]. Furthermore, we measured TPS mRNA
levels and showed statistically signiﬁcant higher values in pa-
tients with M4 compared to other FAB subtypes. Similar re-
sults were obtained by a previous report in which TPS levels
were detected in serum [8].
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Figure 2 Survival analysis for ANLL patients using Kalpan–Meier curve.
Serine protease (TPS): A diagnostic and prognostic marker in pediatric patients with acute non-lymphoblastic leukemia 169In this report, patients with positive TPS showed higher
TLC, lower hemoglobin levels and platelet counts compared
to negative cases with a statistical signiﬁcant difference. Simi-
lar results were also reported previously [13]. Again, we eluci-
dated the value of TPS expression in relation to other
prognostic factors. TPS expression was directly correlated with
total leukocytic counts, absolute blast counts in peripheral
blood, suggesting its correlation with disease severity and tu-
mor burden. Similarly, overexpression of TPS was previously
correlated with poor survival in ANLL [9]. Moreover, we dem-
onstrated that TPS expression was directly correlated with
CD34 and CD117 levels. Previous studies showed that these
ANLL blasts frequently co-express tryptase with additional
mast cell lineage-and/or basophil-related differentiation anti-
gens including CD117 [8].
In this report, after induction chemotherapy TPS levels
were decreased in the eight patients who achieved complete
remission during the follow up period. The rest of the positive
cases (nine patients) revealed statistically higher TPS mRNA
values; ﬁve showed blast cell persistence by bone marrow
examination, and recurred shortly after, during follow up per-
iod. The other four patients showed persistent elevated TPS
expression despite hematologic complete remission, these pa-
tients showed disease recurrence during consolidation treat-
ment. The regrowth of blasts was associated with signiﬁcant
increase in TPS levels. Similar results were obtained by Sperr
et al. [9] who found that the serum TPS levels were initially
high, decreased with treatment and were re-elevated with
the onset of relapse and that hematologic or/and molecular
relapse is accompanied or even preceded by a recurrent in-
crease in TPS [13]. Moreover, previous data showed that per-
sistently elevated TPS in hematologic CR is indicative of
minimal residual ANLL and is a poor prognostic marker with
high risk of relapse [4], which may signiﬁcantly inﬂuence the
treatment plan in these patients [14]. Others explained the
slow decrease in TPS even after a long latent period despite
continuous hematologic CR indicating the time taken until
residual ANLL cells disappear [15,16]. The risk of relapse in
patients with positive TPS expression was six times more fre-
quent than those with negative expression with shorter overall
survival as previously reported [9]. On the contrary, the CR
rate was found previously to be similar in patients withnormal serum TPS compared with those with enhanced en-
zyme levels [5].
In conclusion, TPS is considered as a useful novel marker
for diagnosis and prognosis of myeloid neoplasia. The avail-
ability of such marker for monitoring minimal residual disease
in hematologic complete remission is of major clinical impor-
tance and is helpful in planning treatment in individual pa-
tients with ANLL. Furthermore, anti-TPS could be used as a
suitable target for immunotherapeutic intervention.
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